Navigation Links
Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets
Date:7/14/2009

NEW YORK, July 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson's disease.

Target validation is an essential and historically underresourced phase of drug development in which researchers work to determine whether a molecule or mechanism of interest is a true drug target. While researchers have continued to identify novel targets in recent years through genetic, biochemical and epidemiological studies, a lack of funding for validation studies has long been a major roadblock to the efficient translation of these discoveries into practical therapies that benefit people living with PD.

The Foundation's Target Validation initiative, one of MJFF's Edmond J. Safra Core Programs for PD Research, provides intellectual and financial resources to help push potential PD drug targets one step closer to clinical trials and Parkinson's patients.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

The transcription factor Nrf2 as a target to reduce neurodegeneration and neuroinflammation in Parkinson's disease

Antonio Cuadrado, PhD, Universidad Autonoma de Madrid, Spain

Neuroprotection by PXDNL, a novel heme-containing peroxidase

J. Timothy Greenamyre, MD, PhD, University of Pittsburgh

Validation of Nox1/Rac1, a novel molecular source of reactive oxygen species in the nigrostriatal pathway, as a target for Parkinson's disease therapy

Yoon-Seong Kim, MD, PhD, Weill Medical College of Cornell University

Upregulation of MsrA: A neuroprotective strategy for the treatment of Parkinson's disease

Deniz Kirik, MD, PhD, Lund University (Sweden) and Jean-Christophe Rochet, PhD, Purdue University

Use of Smo1 antagonists to boost endogenous GDNF expression in the adult striatum

Andreas H. Kottman, PhD, Columbia University

Polo-like kinases as therapeutic targets for Parkinson's disease

Hilal A. Lashuel, PhD, and Patrick Aebischer, MD, Ecole Polytechnique Federale de Lausanne (Switzerland) and Deniz Kirik, MD, PhD, Lund University (Sweden)

Validation of cyclophilin D, a protein involved in the mitochondrial permeability transition, as a target for Parkinson's disease therapy

Mathieu Lesort, PhD, University of Alabama at Birmingham

The therapeutic role of CMA-MEF2D in the survival of dopamine neurons

Zixu Mao, PhD, Emory University

SHP-2 phosphatase: A new pharmacological target for Parkinson's disease?

Maria-Cristina Missale, PhD, University of Brescia (Italy)

Validation of Nurr1 as a Drug Target for the Treatment of PD

Demetrios K. Vassilatis, PhD, Foundation for Biomedical Research of the Academy of Athens, Greece

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded over $145 million in research to date.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):